Mga Batayang Estadistika
| LEI | 5493003TER6KY3MUVY84 |
| CIK | 1656634 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Gritstone bio, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| April 4, 2025 |
Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re GRITSTONE BIO, INC.,1 Debtor. Chapter 11 Case No.: 24-12305 (KBO) GRITSTONE BIO, INC.’S SECOND MODIFIED CHAPTER 11 PLAN OF REORGANIZATION March 31, 2025 PACHULSKI STANG ZIEHL & JONES LLP Debra I. Grassgreen (admitted pro hac vice) John W. Lucas (admitted pro hac vice) Malhar S. Pagay (admitted pro hac vice) James |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38663 Gritstone bio, Inc. (Exact name of registrant as specified in its |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| February 25, 2025 |
Exhibit 99.1 Case 24-12305-KBO Doc 451 Filed 02/14/25 page 1 of 12 Docket #0451 Date Filed: 02/14/2025 In Re. Gritstone Bio, Inc. UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Case No. 24-12305 Debtor(s) Monthly Operating Report Reporting Period Ended: 12/31/2024 Jointly Administered Chapter 11 Petition Date: 10/10/2024 Months Pending: 3 Reporting Method: Accrual Basis C Industry Cla |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 14, 2025 |
Exhibit 99.1 Case 24-12305-KBO Doc ~Jta ~ilon n1/1Jt/?t;. C!:llno 1 nf 1? Docket #0349 Date Filed: 01/14/2025 UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In Re. Gritstone Bio, Inc. § Case No. 24-12305—§§ Debtor(s) § D Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 11/30/2024 Petition Date: 10/10/2024—Months Pending: 2 Industry Classification: I 5 4 |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 3, 2025 |
Exhibit 10.1 Execution Version ASSET PURCHASE AGREEMENT by and between SEATTLE PROJECT CORP., as Purchaser, and GRITSTONE BIO, INC., as Seller Dated as of December 30, 2024 Table of Contents Page ARTICLE 1 DEFINED TERMS 1 1.1 Defined Terms 1 1.2 Other Definitional and Interpretive Matters 10 ARTICLE 2 THE PURCHASE AND SALE; CLOSING 13 2.1 Purchase and Sale 13 2.2 Excluded Assets 14 2.3 Assumption |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 29, 2024 |
Exhibit 99.1 Docket #0211 Date Filed: 11/27/2024 UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In Re. Gritstone Bio, Inc. § Case No. 24-12305 § § Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 10/31/2024 Petition Date: 10/10/2024 Months Pending: 1 Industry Classification: 5 4 1 7 Reporting Method: Accrual Basis Cash Basis Debtor’s Full-Ti |
|
| November 15, 2024 |
SENIOR SECURED SUPERPRIORITY DEBTOR-IN-POSSESSION FINANCING AGREEMENT Exhibit 10.1 SENIOR SECURED SUPERPRIORITY DEBTOR-IN-POSSESSION FINANCING AGREEMENT THIS SENIOR SECURED SUPERPRIORITY DEBTOR-IN-POSSESSION FINANCING AGREEMENT (the “Agreement”), dated as of November 13, 2024, is entered into by and among GRITSTONE BIO, INC., a Delaware corporation (“Gritstone” or the “Borrower”), as a debtor and debtor in possession under Chapter 11 of the Bankruptcy Code (as defin |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 16, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 10, 2024 |
Exhibit 99.1 Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure Voluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties EMERYVILLE, Calif. -(BUSINESS WIRE)- Oct. 10, 2024 – Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to develop the world’s most |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 7, 2024 |
GRTS / Gritstone bio, Inc. / RedCo II Master Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Gritstone bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 39868T105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 13, 2024 |
Exhibit 99.1 Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 - - Recent |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| August 13, 2024 |
Second Amendment to Office Building Net Lease Agreement effective as of May 10, 2024. Exhibit 10.1 SECOND AMENDMENT TO OFFICE BUILDING NET LEASE This Second Amendment to Office Building Net Lease (this “Second Amendment”) is made and entered into as of May 10, 2024 (the “Effective Date”), by and between the undersigned owners of the Property (formerly Hacienda Portfolio Venture, LLC, a Delaware limited liability company (“Landlord”), and Gritstone bio, Inc. (formerly known as Grits |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 10, 2024 |
DEFA14A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 9, 2024 |
Exhibit 99.1 Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates - Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024 |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 2, 2024 |
EX-4.2 Exhibit 4.2 WARRANT NO. 2024-[●] NUMBER OF SHARES: [●] (subject to adjustment hereunder) DATE OF ISSUANCE: [●], 2024 EXPIRATION DATE: The first date on which no shares of Common Stock are issuable upon a cash exercise of this Warrant PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK OF GRITSTONE BIO, INC. This Warrant (the “Warrant”) is issued by Gritstone bio, Inc., a Delaware corporat |
|
| April 2, 2024 |
Underwriting Agreement, dated April 1, 2024. Exhibit 1.1 Gritstone bio, Inc. 8,333,333 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 13,334,222 Shares of Common Stock Common Warrants to Purchase 21,667,555 Shares of Common Stock (or Pre-Funded Warrants in Lieu Thereof) Underwriting Agreement April 1, 2024 TD Securities (USA) LLC Evercore Group L.L.C. As representatives (the “Representatives”) of the seve |
|
| April 2, 2024 |
Exhibit 4.1 WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS GRITSTONE BIO, INC. Warrant Shares: Initial Exercise Date: April [•], 2024 THIS WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| April 2, 2024 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263455 PROSPECTUS SUPPLEMENT (To prospectus dated May 6, 2022) 8,333,333 Shares of Common Stock Pre-Funded Warrants to Purchase 13,334,222 Shares of Common Stock Common Warrants to Purchase 21,667,555 Shares of Common Stock or Pre-Funded Warrants We are offering 8,333,333 shares of our common stock, in lieu of common sto |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 1, 2024 |
SUBJECT TO COMPLETION, DATED APRIL 1, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263455 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi |
|
| March 5, 2024 |
Exhibit 99.1 Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates - Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 - - National Cancer Institute-led Phase 1 study evaluating G |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 5, 2024 |
Registrant's Policy to Recovery of Erroneously Awarded Compensation Exhibit 97.1 GRITSTONE BIO, INC. COMPENSATION RECOVERY POLICY EFFECTIVE NOVEMBER 14, 2023 1. PURPOSE 1.1. The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement due to material |
|
| March 5, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Gritstone bio, Inc. |
|
| March 5, 2024 |
Amended and Restated Non-Employee Director Compensation Program. Exhibit 10.10 AMENDED AND RESTATED GRITSTONE BIO, INC. (F/K/A GRITSTONE ONCOLOGY, INC.) NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Amended and Restated Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc. (the “Company”)) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2018 Incentive Award Plan (the “Plan”) and shall be effective upon November 1 |
|
| March 5, 2024 |
As filed with the Securities and Exchange Commission on March 5, 2024 As filed with the Securities and Exchange Commission on March 5, 2024 Registration No. |
|
| March 5, 2024 |
Exhibit 10.27 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00001 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. 5 |
|
| March 5, 2024 |
Exhibit 10.30 FIRST AMENDMENT TO LEASE AND TERM COMMENCEMENT DATE AGREEMENT THIS FIRST AMENDMENT TO LEASE AND TERM COMMENCEMENT DATE AGREEMENT (this “Agreement”) is entered into as of this 20 day of September 2023 (“Effective Date”), by and between RREF II Kenmore Lessor III LLC and RREF II Kenmore Lessor IV LLC (collectively, “Landlord”), and Gritstone bio, Inc., a Delaware corporation (“Tenant”) |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38663 Gritstone bio, |
|
| March 5, 2024 |
Consent of Fenwick & West LLP (included in Exhibit 5.1) Exhibit 5.1 March 5, 2024 Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, CA 94608 Re: Registration Statement on Form S-8 Ladies and Gentlemen: As counsel to Gritstone bio, Inc., a Delaware corporation (the “Company”), we have examined the Registration Statement on Form S-8 (the “Registration Statement”) to be filed by the Company with the Securities and Exchange Commission (the “Com |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 14, 2024 |
GRTS / Gritstone bio, Inc. / Point72 Asset Management, L.P. - GRITSTONE BIO, INC. Passive Investment SC 13G/A 1 p24-0806sc13ga.htm GRITSTONE BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Gritstone bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 14, 2024 |
GRTS / Gritstone bio, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d14sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7) Gritstone bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2024 |
EX-99.1 2 tm245846d14ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 |
|
| February 13, 2024 |
GRTS / Gritstone bio, Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 13, 2024 |
EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Gritstone bio, Inc. Date: February 13, 2024 FRAZIER HEALTHCARE VII, L.P. By FHM VII, L.P., its general pa |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 27, 2023 |
GRITSTONE BIO, INC. 5959 Horton Street, Suite 300 Emeryville, California 94608 GRITSTONE BIO, INC. 5959 Horton Street, Suite 300 Emeryville, California 94608 December 27, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jessica Dickerson Re: Gritstone bio, Inc. Registration Statement on Form S-3 (File No. 333- 276242) filed December 22, 2023 Requested Date: December 29, 2023 Req |
|
| December 22, 2023 |
Exhibit 107 Calculation of Fee Filing Tables Form S-3 (Form Type) Gritstone bio, Inc. |
|
| December 22, 2023 |
Exhibit 4.5 FORM OF DEBT SECURITY [Face of Security] GRITSTONE BIO, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURIT |
|
| December 22, 2023 |
As filed with the Securities and Exchange Commission on December 22, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 22, 2023 Registration No. |
|
| December 22, 2023 |
Exhibit 4.6 GRITSTONE BIO, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXECUTION |
|
| November 8, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER ☑ UNDER DPAS (15 CFR 700) RATING PAGE OF PAGES 1 2 2. CONTRACT (Proc. Inst. Ident.) NO. 75A50123C00062 3. EFFECTIVE DATE See Block 20C 4. REQUIS |
|
| November 8, 2023 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. NONEXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT by and between GRITSTONE ONCOLOGY, INC. on the one hand, and GENEVANT SCIENCES GMBH on the other hand Dated as of January 15, 2021 1 NONEXCLUSIVE |
|
| November 8, 2023 |
Exhibit 99.1 Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates - BARDA contract and IDWeek presentations position Gritstone’s self-amplifying mRNA (samRNA) as a leading next-generation approach to COVID-19 prevention; preparations underway for Phase 2b head-to-head study evaluating samRNA candidate versus an approved COVID-19 vaccine - - Preliminary data fro |
|
| November 8, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Amendment No. 1 to nonexclusive License and Development Agreement This Amendment No. 1 to Nonexclusive License and Development Agreement (this “Amendment”), effective as of the date signed by t |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 8, 2023 |
wa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q wa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gr |
|
| September 27, 2023 |
Exhibit 99.1 Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million — 10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets with an approved vaccine against COVID-19 — — Contract is part |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 9, 2023 |
Exhibit 99.1 Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates - Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); preliminary efficacy data expected in 1Q 2024 - - Gritstone partnering with Friends of Cancer Research ( |
|
| August 9, 2023 |
wa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q wa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritsto |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 11, 2023 |
Exhibit 99.1 Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates - Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023- - Gritstone prioritizing GRANITE; expanding Ph |
|
| May 11, 2023 |
Certain information has been omitted from this Exhibit 10.1 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions. Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of July 19, 2022 and is entered into by and among GRITSTONE BIO, Inc., a Delaware cor |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| April 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 26, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission File |
|
| April 6, 2023 |
EX-10.1 Exhibit 10.1 Certain information has been omitted from this Exhibit 10.1 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 31, 2023 (the “Amendme |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38663 Gritstone bio, |
|
| March 9, 2023 |
Exhibit 10.22 Fifth Amendment to License Agreement This Fifth Amendment to License Agreement (“Fifth Amendment”) is dated June 13, 2022 (“Effective Date”) and entered into by and between Gritstone bio, Inc., formerly known as Gritstone Oncology, Inc. (“Licensee”) and MIL 21E, LLC (“Licensor”). WHEREAS, Licensor and Licensee are parties to a certain License Agreement dated September 6, 2018, as ame |
|
| March 9, 2023 |
EX-FILING FEES Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Gritstone bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed maximum offering price per unit Maximum aggregate offering price Fee Rate Amount of Registration Fee Equity Common sto |
|
| March 9, 2023 |
Exhibit 99.1 Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates - Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 - - Phase 1/2 efficacy signals from “off-the-shelf” vaccine program (SLATE) consistent with those from GRANITE; rando |
|
| March 9, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023 S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| February 14, 2023 |
GRTS / Gritstone Oncology Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d994240313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Gritstone bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 14, 2023 |
GRTS / Gritstone Oncology Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) Gritstone bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Gritstone bio, Inc. (Title of Cl |
|
| February 14, 2023 |
SC 13G/A 1 d449268dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Gritstone bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 39868T 105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2023 |
EX-99.1 2 tm236041d6ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 p |
|
| February 14, 2023 |
EX-99.A 2 d449268dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Gritstone bio, Inc. Date: February 14, 2023 FRAZIER HEALTHCARE VII, L.P. By F |
|
| February 10, 2023 |
GRTS / Gritstone Oncology Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Gritstone bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2023 |
GRTS / Gritstone Oncology Inc / Versant Venture Capital V, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3) Gritstone Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 39868T105 (CUSIP Nu |
|
| February 3, 2023 |
GRTS / Gritstone Oncology Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING GRITSTONE BIO INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 39868T105 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 14, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268524 PROSPECTUS Gritstone bio, Inc. 6,637,165 Shares of Common Stock 13,274,923 Shares of Common Stock Issuable upon Exercise of Pre- Funded Warrant This prospectus relates to the proposed resale or other disposition from time to time of up to (i) 6,637,165 shares of our common stock, par value $0.0001 per share (the ?Common |
|
| November 28, 2022 |
Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 November 28, 2022 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: Gritstone bio, Inc. Registration Statement on Form S-3 (Registration No. 333-268524) To the addressees set forth above: In accordance with Rule 461 unde |
|
| November 22, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON November 22, 2022 S-3 1 d333951ds3.htm S-3 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON November 22, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Gritstone bio, Inc. (Exact name of Registrant as specified in its charter) Delaware 2836 47-4859534 (State or other jurisdic |
|
| November 22, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Gritstone bio, Inc. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Grits |
|
| November 3, 2022 |
Exhibit 99.1 Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update - Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application of self-amplifying mRNA (samRNA) as infectious disease vaccine platform - - Initial Phase 2 data from KRAS-directed SLATE ("off-the-shelf" neoantigen program) show similar signals in non- |
|
| November 3, 2022 |
Certain information has been omitted from this Exhibit 10.1 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions. Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of July 19, 2022 and is entered into by and among GRITSTONE BIO, Inc., a Delaware cor |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 1, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| November 1, 2022 |
GRTS / Gritstone Oncology Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Gritstone bio, Inc. (Title of Class of Securities) Common Stock, Par Value $0.0001 Per |
|
| October 25, 2022 |
Form of Pre-Funded Warrant issued in Third PIPE Financing. EX-4.1 2 d341720dex41.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT |
|
| October 25, 2022 |
Securities Purchase Agreement, dated October 24, 2022 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 24, 2022 (the “Effective Date”), among Gritstone bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company and the Purchasers are executing an |
|
| October 25, 2022 |
EX-99.1 Exhibit 99.1 Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases — New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination — — Interim results from CORAL-CEPI show good tolerabil |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2022 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 10, 2022 |
Exhibit 99.1 Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors - Expert in virology, immunology and vaccine development’s appointment effective August 12 - EMERYVILLE, CALIF. – August 10, 2022 (GLOBE NEWSWIRE) – Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced the appointment of L |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 4, 2022 |
Exhibit 10.1 Fourth Amendment to License Agreement This Fourth Amendment to License Agreement (?Fourth Amendment?) is dated June 6, 2022 (?Effective Date?) and entered into by and between Gritstone bio, Inc., formerly known as Gritstone Oncology, Inc. (?Licensee?) and MIL 21E, LLC (?Licensor?). WHEREAS, Licensor and Licensee are parties to a certain License Agreement dated September 6, 2018, as am |
|
| August 4, 2022 |
Exhibit 99.1 Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update - Clinical programs continue to progress, with initial data from Phase 2 study of ?off the shelf? SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program (CORAL) expected this year - - Follow up data from subset of CORAL-BOOST study shows strong neutralizing antibody titers persisted |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission File |
|
| July 22, 2022 |
Exhibit 99.1 Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and Silicon Valley Bank July 21, 2022 EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) ? Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world?s most potent vaccines, today announced it has entered into an $80 million credit facility with Hercules Cap |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 10, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2022 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No 333-263455 PROSPECTUS SUPPLEMENT (To prospectus dated May 6, 2022) $100,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. |
|
| May 9, 2022 |
As filed with the Securities and Exchange Commission on May 9, 2022 S-8 1 d684886ds8.htm S-8 As filed with the Securities and Exchange Commission on May 9, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Gritstone bio, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-4859534 (State or other jurisdiction of incorporation or orga |
|
| May 9, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Gritstone bio, Inc. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| May 3, 2022 |
Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 CORRESP 1 filename1.htm Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 May 3, 2022 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: Gritstone bio, Inc. Registration Statement on Form S-3 (Registration No. 333-263455) To the addressees set forth above: In accordance |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| April 28, 2022 |
DEF 14A 1 ny20002602x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Prox |
|
| March 21, 2022 |
Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 March 21, 2022 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: Gritstone bio, Inc. Withdrawal of Acceleration Request for Registration Statement on Form S-3 (Registration No. 333-263455) To the addressees set forth abo |
|
| March 16, 2022 |
Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 CORRESP 1 filename1.htm Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 March 16, 2022 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: Gritstone bio, Inc. Registration Statement on Form S-3 (Registration No. 333-263455) To the addressees set forth above: In accordan |
|
| March 10, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 10, 2022, Gritstone bio, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following summary describes our common stock and the material provisions of our amended and res |
|
| March 10, 2022 |
As filed with the Securities and Exchange Commission on March 10, 2022 As filed with the Securities and Exchange Commission on March 10, 2022 Registration No. |
|
| March 10, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Gritstone bio, Inc. |
|
| March 10, 2022 |
Sales Agreement, dated March 10, 2022, by and between Gritstone bio, Inc. and Cowen and Company, LLC Exhibit 1.2 GRITSTONE BIO, INC. $100,000,000 COMMON STOCK SALES AGREEMENT March 10, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Gritstone bio, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to ti |
|
| March 10, 2022 |
Exhibit 10.10 GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into as of June 14, 2021 (the ?Effective Date?), is between Gritstone bio, Inc., a Delaware corporation (the ?Company?) and Vassiliki Economides (?Executive? and, together with the Company, the ?Parties?). WHEREAS, the Company desires to engage Executive to perform services as an employ |
|
| March 10, 2022 |
Amended and Restated Non-Employee Director Compensation Program. Exhibit 10.11 AMENDED AND RESTATED GRITSTONE BIO, INC. (F/K/A GRITSTONE ONCOLOGY, INC.) NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Amended and Restated Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc. (the ?Company?)) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2018 Incentive Award Plan (the ?Plan?) and shall be effective upon March 8, 2 |
|
| March 10, 2022 |
Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions. Exhibit 10.3 COLLABORATION, Option AND LICENSE AGREEMENT by and between gilead sciences, Inc. and Gritstone oncology, inc. Certain identified information has been omitte |
|
| March 10, 2022 |
Exhibit 4.4 GRITSTONE BIO, INC. INDENTURE Dated as of , 20 [ ], as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Est |
|
| March 10, 2022 |
As filed with the Securities and Exchange Commission on March 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 10, 2022 Registration No. |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38663 Gritstone bio, |
|
| March 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Gritstone bio, Inc. |
|
| February 14, 2022 |
GRTS / Gritstone Oncology Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5) Gritstone bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
GRTS / Gritstone Oncology Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.0001 par value per share, of Gritstone bio, Inc., |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Gritstone bio, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 39868T105 (CUSIP Number) Dec |
|
| February 14, 2022 |
GRTS / Gritstone Oncology Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Gritstone Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 11, 2022 |
GRTS / Gritstone Oncology Inc / Versant Venture Capital V, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d270582dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2) Gritstone Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of S |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Gritstone Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 4, 2022 |
Investor Presentation January 2022 Exhibit 99.2 Disclaimer This presentation and accompanying oral presentation, if any, contain forward-looking statements including, but not limited to, statements related to Gritstone bio, Inc.?s (?Gritstone?, ?we? or ?our?) preclinical and clinical product candidates, including GRANITE, SLATE, CORAL, and HIV programs. All statements other than statements of hist |
|
| January 4, 2022 |
Exhibit 99.1 Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19 ? Single 10 ?g dose of samRNA vaccine containing Spike plus additional T cell epitopes (TCE) induced robust neutralizing antibody titers in ten healthy adults ?60yrs who had received two prior doses of Astr |
|
| January 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 17, 2021 |
Exhibit 99.1 Gritstone Announces Changes to Its Board of Directors - Clare Fisher, accomplished corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1, 2022 - - Judith J. Li, partner at Lilly Asia Ventures, will depart the Board effective January 1, 2022 - EMERYVILLE, CALIF. ? December 17, |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Grits |
|
| October 29, 2021 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 29, 2021 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 29, 2021 Registration No. |
|
| October 29, 2021 |
Gritstone bio, Inc. 5,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No 333-260292 PROSPECTUS Gritstone bio, Inc. |
|
| October 27, 2021 |
Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 Gritstone bio, Inc. 5959 Horton Street, Suite 300 Emeryville, California 94608 October 27, 2021 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: Gritstone bio, Inc. Registration Statement on Form S-3 (Registration No. 333-260292) To the addressees set forth above: In accordance with Rule 461 under |
|
| October 15, 2021 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 15, 2021 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 15, 2021 Registration No. |
|
| September 29, 2021 |
Exhibit 10.1 LEASE Between RREF II Kenmore Lessor III LLC and RREF II Kenmore Lessor IV LLC, as Landlord and Gritstone bio, Inc., as Tenant At The Beacon Building Boston, Massachusetts 1 EXHIBIT 1, SHEET 1 The Beacon Building 650-660 Beacon Street, 648 Beacon Street Boston, Massachusetts Effective Date: September 23, 2021 Tenant: Gritstone bio, Inc., a Delaware Corporation Tenant Mailing Address: |
|
| September 29, 2021 |
Exhibit 10.2 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 21st day of September, 2021, by and between BMR-Sidney Research Campus LLC, a Delaware limited liability company (?Landlord?), and Gritstone Bio, Inc. (f/k/a Gritstone Oncology, Inc.), a Delaware corporation (?Tenant?). RECITALS A. WHEREAS, Landlord and Tenant are parties to that certa |
|
| September 29, 2021 |
Exhibit 10.3 Third Amendment to License Agreement This Third Amendment to License Agreement (?Third Amendment?) is made as of September 21, 2021, by and between Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc.) (?Licensee?) and MIL 21E, LLC (?Licensor?). WHEREAS, Licensor and Licensee are parties to a certain License Agreement dated September 6, 2018, as amended by that certain First Amendment |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2021 Gritstone bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38663 47-4859534 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 27, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.0001 par value per share, of Gritstone bio, Inc., |
|
| September 27, 2021 |
GRTS / Gritstone Oncology Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4) GRITSTONE BIO, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 39868T105 (CUSIP Number) September 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| September 21, 2021 |
GRTS / Gritstone Oncology Inc / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| September 21, 2021 |
EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Gritstone bio, Inc. |
|
| September 17, 2021 |
Securities Purchase Agreement, dated as of September 16, 2021. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 16, 2021 (the ?Effective Date?), among Gritstone bio, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, the Company and the Purchasers are executing and deli |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission |
|
| August 17, 2021 |
Exhibit 99.1 Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern ? CEPI to fund Gritstone?s work on second-generation vaccines against SARS-CoV-2, the virus causing COVID-19, including a clinical trial in South Africa and manufacturing optimization ? Gritstone?s second-generation vaccines include self-amplifying |
|
| August 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| August 5, 2021 |
Exhibit 10.1 Amendment #3 to Research Collaboration and License Agreement This Amendment #3 (?Amendment?) to the Research Collaboration and License Agreement is made by and between Gritstone Oncology, Inc. (?Gritstone?) and Bluebird Bio, Inc. (?Bluebird?). This Amendment is effective as of February 18, 2021 (the ?Amendment Effective Date?). WHEREAS, Gritstone and Bluebird are parties to that Resea |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2021 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission File |
|
| June 23, 2021 |
Exhibit 99.1 Gritstone Announces Management Changes, Including the Appointment of Celia Economides as Chief Financial Officer EMERYVILLE, CALIF. ? June 23, 2021 (GLOBE NEWSWIRE) ? Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced the appointment of Celia Economides as executive vice p |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission File |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 6, 2021 |
Form of Stock Option Agreement under the 2021 Employment Inducement Incentive Plan. Exhibit 99.2 GRITSTONE BIO, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Gritstone bio, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Employment Inducement Incentive Award Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an option to purchase the number of shares of the Company? |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| May 6, 2021 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Gritstone Oncology, Inc. resolutions were duly adopted setting forth a proposed amendment of the Certificate of Incorporati |
|
| May 6, 2021 |
2021 Employment Inducement Incentive Plan. Exhibit 99.1 GRITSTONE BIO, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate employees who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and ph |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 Gritstone bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 6, 2021 |
Form of Restricted Stock Unit Award Agreement under the 2021 Employment Inducement Incentive Plan. Exhibit 99.3 GRITSTONE BIO, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE Gritstone bio, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Employment Inducement Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?) the number of shares of the Company?s Common Stock s |
|
| May 6, 2021 |
As filed with the Securities and Exchange Commission on May 6, 2021 Registration No. |
|
| May 6, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF GRITSTONE BIO, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I?CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II?MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR NOMINA |
|
| May 6, 2021 |
Form of Stock Award Agreement under the 2021 Employment Inducement Incentive Plan. Exhibit 99.4 GRITSTONE BIO, INC. 2021 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Gritstone bio, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2021 Employment Inducement Incentive Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of restricted stock units (?Restricte |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Stat |
|
| April 23, 2021 |
DEF 14A 1 nc10021759x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Gritstone Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 39868T105 (CUSIP Number) March 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38663 Gritstone Oncol |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commission |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1) Gritstone Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 39868T105 (CUSIP Nu |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Gritstone Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 39868T105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 16, 2021 |
EX-99.1 Exhibit 1 Joint Filing Agreement We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Gritstone Oncology, Inc. is filed on behalf of each of us. February , 2021 Versant Venture Capital V, L.P. By: Versant Ventures V, LLC Its: General Partner By: /s/ Robin L. Praeger Robin L. Praeger, Managing Director V |
|
| February 16, 2021 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Gritstone Oncology, I |
|
| February 16, 2021 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Gritstone Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 39868T105 (CUSIP Number) January 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 4, 2021 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 1, 2021 |
Stock Purchase Agreement, dated January 29, 2021* EX-10.1 Exhibit 10.1 EXECUTION VERSION GRITSTONE ONCOLOGY, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (“Agreement”) is made as of January 29, 2021 (the “Effective Date”), by and between Gritstone Oncology, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (the “Purchaser”). RECITALS A. The Company and the Purchaser have entered into th |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commissi |
|
| February 1, 2021 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commissi |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Gritstone Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 39868T105 (CUSIP Number) January 21, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 1, 2021 |
Stockholder Agreement, dated January 29, 2021* EX-10.2 Exhibit 10.2 EXECUTION VERSION STOCKHOLDER AGREEMENT by and between GRITSTONE ONCOLOGY, INC. and GILEAD SCIENCES, INC. Dated as of January 29, 2021 STOCKHOLDER AGREEMENT THIS STOCKHOLDER AGREEMENT (this “Agreement”), dated as of January 29, 2021, is by and between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Gilead Sciences, Inc., a Delaware corporation (the “Invest |
|
| January 29, 2021 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 29, 2021 Registration No. |
|
| January 29, 2021 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252564 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Security(2) Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.0001 per share 9,586,478 $18.62 $178,500,220.36 $19,475 Commo |
|
| January 29, 2021 |
EX-4.4 Exhibit 4.4 GRITSTONE ONCOLOGY, INC. INDENTURE Dated as of , 202 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. |
|
| January 22, 2021 |
Entry into a Material Definitive Agreement, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2021 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commissi |
|
| January 11, 2021 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 11, 2021 with respect to the shares of Common Stock, $0.0001 par value per share, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) und |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Gritstone Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 39868T105 (CUSIP Number) |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Gritstone Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 39868T105 (CUSIP Number) December 28, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| December 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commiss |
|
| December 30, 2020 |
Securities Purchase Agreement, dated December 28, 2020 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 28, 2020 (the “Effective Date”), among Gritstone Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company and the Purchasers are execut |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 28, 2020 |
EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commiss |
|
| December 28, 2020 |
Securities Purchase Agreement, dated December 22, 2020 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 22, 2020 (the “Effective Date”), among Gritstone Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company and the Purchasers are execut |
|
| December 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commiss |
|
| November 5, 2020 |
Exhibit 10.1 Amendment #2 to Research Collaboration and License Agreement This Amendment #2 (“Amendment”) to the Research Collaboration and License Agreement is made by and between Gritstone Oncology, Inc. (“Gritstone”) and Bluebird Bio, Inc. (“Bluebird”). This Amendment is effective as of August 19, 2020 (the “Amendment Effective Date”). WHEREAS, Gritstone and Bluebird are parties to that Researc |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Grits |
|
| October 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commissi |
|
| August 5, 2020 |
Exhibit 10.1 Second Amendment to License Agreement This Second Amendment to License Agreement (“Second Amendment”), is made as of May 20, 2020 (“Effective Date”) by and between Gritstone Oncology, Inc. (“Licensee”) and MIL 21E, LLC (“Licensor”). WHEREAS, Licensor and Licensee are parties to a certain License Agreement dated September 6, 2018, as amended by a certain First Amendment to License Agre |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| July 13, 2020 |
EX-99.1 Exhibit 99.1 Clinical Data Update & Near-term Phase 2 Plans 13 July 2020 1Exhibit 99.1 Clinical Data Update & Near-term Phase 2 Plans 13 July 2020 1 Safe Harbor and Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to our preclinical and clinical product candidates, GRANITE, SLATE, and our bispecific antibody |
|
| July 13, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commiss |
|
| June 19, 2020 |
Submission of Matters to a Vote of Security Holders 8-K 1 d949340d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of in |
|
| May 7, 2020 |
Exhibit 10.1 GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into as of March 2, 2020 (the “Effective Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Rahsaan Thompson (“Executive” and, together with the Company, the “Parties”). WHEREAS, the Company desires to engage Executive to perform services as an employ |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38663 Gritstone |
|
| May 1, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2020 Gritstone Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38663 47-4859534 (State or other jurisdiction of incorporation) (Commissio |
|
| May 1, 2020 |
EX-99.1 Exhibit 99.1 Gritstone Oncology Announces the Appointment of Dr. Elaine V. Jones as Chair of the Board of Directors EMERYVILLE, CALIF. – May 1, 2020 (GLOBE NEWSWIRE) – Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the appointment of Elaine V. Jones, Ph. |
|
| April 24, 2020 |
Definitive Proxy Statement on Schedule 14A DEF 14A 1 nc10010691x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| April 24, 2020 |
DEFA14A 1 nc10010692x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
